Početna › Rak prostate › Nebraska
Kliničke studije za Rak prostate u državi Nebraska
27 studija za Rak prostate traži sudionike na lokacijama u državi Nebraska.
Gradovi u državi Nebraska
Službeni tekst studije (engleski)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- i još 2
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT03866382Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Urology Cancer Center, PC, Omaha
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Muškarci · Ažurirano 25. ruj 2026. · NCT06800313A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026), Omaha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06136650Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Nebraska Cancer Specialists, Omaha
U tijeku regrutacijaFaza 2/3
Od 18 do 100 godina · Muškarci · Ažurirano 22. ruj 2026. · NCT06780670Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Nebraska Cancer Specialists, Omaha
U tijeku regrutacijaFaza 3
Od 18 do 100 godina · Muškarci · Ažurirano 22. ruj 2026. · NCT06855277PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
- University of Nebraska Medical Center, Omaha
U tijeku regrutacijaFaza 2
Od 30 godina i više · Muškarci · Ažurirano 21. ruj 2026. · NCT07234981A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
- XCancer, Omaha
U tijeku regrutacijaFaza 1
Od 18 godina i više · Muškarci · Ažurirano 15. ruj 2026. · NCT07581184Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- XCancer Omaha LLC, Omaha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 11. ruj 2026. · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 10. ruj 2026. · NCT05946213Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Research Site, Omaha
U tijeku regrutacijaFaza 1/2
Od 18 do 99 godina · Muškarci · Ažurirano 27. kol 2026. · NCT07590934AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Omaha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 26. kol 2026. · NCT07611110Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- XCancer Omaha, Omaha
U tijeku regrutacijaFaza 2
Od 18 godina i više · Muškarci · Ažurirano 24. kol 2026. · NCT07745361A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- Nebraska Cancer Specialists, Omaha
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Muškarci · Ažurirano 20. kol 2026. · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- CHI Health Good Samaritan, Kearney
- Alegent Health Bergan Mercy Medical Center, Omaha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 19. kol 2026. · NCT04423211Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
- University of Nebraska Medical Center, Omaha
U tijeku regrutacijaFaza 2
Od 30 godina i više · Muškarci · Ažurirano 19. kol 2026. · NCT07237269Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- i još 2
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 14. srp 2026. · NCT06592924Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- i još 3
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 11. lip 2026. · NCT05283330Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Urology Cancer Center PC, Omaha
- Nebraska Cancer Specialists, Omaha
U tijeku regrutacijaFaza 4
Od 18 do 100 godina · Muškarci · Ažurirano 4. lip 2026. · NCT05803941Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
- XCancer Omaha / Urology Cancer Center, Omaha
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Muškarci · Ažurirano 14. svi 2026. · NCT05413850A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Research Site, Omaha
U tijeku regrutacijaFaza 1
Od 18 godina i više · Muškarci · Ažurirano 12. svi 2026. · NCT06879041Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- CHI Health Good Samaritan, Kearney
- Saint Elizabeth Regional Medical Center, Lincoln
- Alegent Health Immanuel Medical Center, Omaha
- i još 4
U tijeku regrutacijaFaza 2
Od 18 godina i više · Muškarci · Ažurirano 29. sij 2026. · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 22. sij 2026. · NCT06470243High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
- University of Nebraska Medical Center, Omaha
U tijeku regrutacija
Od 19 godina i više · Muškarci · Ažurirano 5. stu 2025. · NCT05754580SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Muškarci · Ažurirano 11. ruj 2025. · NCT03678025Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.